

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 27, 2025**

---

**INHIBIKASE THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39676**  
(Commission  
File Number)

**26-3407249**  
(IRS Employer  
Identification No.)

**1000 N. West Street, Suite 1200**  
**Wilmington, DE**  
(Address of Principal Executive Offices)

**19801**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (302) 295-3800**

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <b>Title of each class</b>      | <b>Trading<br/>Symbol(s)</b> | <b>Name of each exchange<br/>on which registered</b> |
|---------------------------------|------------------------------|--|
| Common Stock, \$0.001 par value | IKT                          | The Nasdaq Stock Market LLC                          |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The 2025 Annual Meeting of Stockholders (the “**Annual Meeting**”) of Inhibikase Therapeutics, Inc. (the “**Company**”) was held on June 27, 2025. The following proposals were approved at the Annual Meeting by the votes indicated:

Proposal One: To elect two Class II directors, Amit Munshi and David Canner, Ph.D., to the Board of Directors, each to serve until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

Amit Munshi and David Canner, Ph.D. were duly elected to the Board of Directors as Class II directors, each to serve until the Company’s 2028 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation or removal:

| Name                | Total Votes<br>for Director | Total Votes<br>withheld from<br>Director | Total Broker<br>Non-Votes |
|---------------------|-----------------------------|--|---------------------------|
| Amit Munshi         | 56,789,636                  | 914,072                                  | 3,404,865                 |
| David Canner, Ph.D. | 57,684,839                  | 18,869                                   | 3,404,865                 |

Proposal Two: To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

|                  | Total Votes |
|------------------|-------------|
| For              | 61,078,342  |
| Against          | 29,037      |
| Abstain          | 1,194       |
| Broker Non-Votes | 0           |

Proposal Three: To approve an amendment to the Company’s 2020 Equity Incentive Plan to include an automatic “evergreen” provision and to extend the term of such plan.

|                  | Total Votes |
|------------------|-------------|
| For              | 46,263,058  |
| Against          | 11,381,113  |
| Abstain          | 59,537      |
| Broker Non-Votes | 3,404,865   |

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 30, 2025

INHIBIKASE THERAPEUTICS, INC.

By: /s/ Mark Iwicki

Mark Iwicki  
Chief Executive Officer